UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Predicting transporter‐mediated drug interactions: Commentary on: “Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin and rosuvastatin” and “Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A”

Clinical pharmacology and therapeutics, 2017-04, Vol.101 (4), p.447-449

2017

Volltextzugriff (PDF)

Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity

Clinical pharmacology and therapeutics, 2009-10, Vol.86 (4), p.396-402

2009

Volltextzugriff (PDF)

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

European journal of cancer (1990), 2001-09, Vol.37 (13), p.1590-1598

2001

Volltextzugriff (PDF)

Drug Transporters: Advances and Opportunities

Clinical pharmacology and therapeutics, 2016-11, Vol.100 (5), p.398-403

2016

Volltextzugriff (PDF)

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations

British journal of cancer, 2014-02, Vol.110 (4), p.894-898

2014

Volltextzugriff (PDF)

Pharmacogenetics of drug transporters

Current pharmaceutical design, 2010, Vol.16 (2), p.220-230

2010

Volltextzugriff (PDF)

Peripheral neuropathy: A persisting challenge in paclitaxel-based regimes

European journal of cancer (1990), 2006, Vol.42 (1), p.24-30

2006

Volltextzugriff (PDF)

Pharmacogenetic Pathway Analysis of Docetaxel Elimination

Clinical pharmacology and therapeutics, 2009-02, Vol.85 (2), p.155-163

2009

Volltextzugriff (PDF)

A Snapshot of Challenges and Solutions in Cancer Drug Development and Therapy

Clinical pharmacology and therapeutics, 2014-04, Vol.95 (4), p.341-346

2014

Volltextzugriff (PDF)

Dosing strategies for anticancer drugs: the good, the bad and body-surface area

European journal of cancer (1990), 2002-09, Vol.38 (13), p.1677-1684

2002

Volltextzugriff (PDF)

Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy

Clinical pharmacokinetics, 2003-01, Vol.42 (7), p.665-685

2003

Volltextzugriff (PDF)

Advances in Cancer Therapeutics

Clinical pharmacology and therapeutics, 2009-02, Vol.85 (2), p.113-117

2009

Volltextzugriff (PDF)

Integrating Clinical Pharmacology Concepts in Individualized Therapy With Tyrosine Kinase Inhibitors

Clinical pharmacology and therapeutics, 2013-03, Vol.93 (3), p.215-219

2013

Volltextzugriff (PDF)

Conjunctive Therapy of Cisplatin With the OCT2 Inhibitor Cimetidine: Influence on Antitumor Efficacy and Systemic Clearance

Clinical pharmacology and therapeutics, 2013-11, Vol.94 (5), p.585-592

2013

Volltextzugriff (PDF)

Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11)

Clinical cancer research, 2001-08, Vol.7 (8), p.2182-2194

2001

Volltextzugriff (PDF)

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

JNCI : Journal of the National Cancer Institute, 2002-12, Vol.94 (24), p.1883-1888

2002

Volltextzugriff (PDF)

Irinotecan-induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein

Clinical pharmacology and therapeutics, 2007-01, Vol.81 (1), p.42-49

2007

Volltextzugriff (PDF)

Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents

British journal of cancer, 2012-09, Vol.107 (7), p.1100-1106

2012

Volltextzugriff (PDF)

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations

British journal of cancer, 2017-08, Vol.117 (5), p.e3-e3

2017

Volltextzugriff (PDF)

Drug Trafficking: Recent Advances in Therapeutics and Disease

Clinical pharmacology and therapeutics, 2012-11, Vol.92 (5), p.531-534

2012

Volltextzugriff (PDF)

Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia

Clinical pharmacology and therapeutics, 2016-06, Vol.99 (6), p.651-660

2016

Volltextzugriff (PDF)

Associations Between ABCC2 Polymorphisms and Cisplatin Disposition and Efficacy

Clinical pharmacology and therapeutics, 2012-06, Vol.91 (6), p.1022-1026

2012

Volltextzugriff (PDF)

Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2

Clinical pharmacology and therapeutics, 2011-06, Vol.89 (6), p.816-820

2011

Volltextzugriff (PDF)

Influence of Solute Carriers on the Pharmacokinetics of CYP3A4 Probes

Clinical pharmacology and therapeutics, 2008-12, Vol.84 (6), p.704-709

2008

Volltextzugriff (PDF)

Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics

Clinical pharmacology and therapeutics, 2007-01, Vol.81 (1), p.76-82

2007

Volltextzugriff (PDF)

1 – 25 von 674

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(611)
Mit Volltextzugriff
(602)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(447)
Life Sciences & Biomedicine
(420)
Humans
(369)
Oncology
(219)
Female
(206)
Biological And Medical Sciences
(189)
Medical Sciences
(185)
Male
(178)
Pharmacology. Drug Treatments
(163)
Middle Aged
(133)
Animals
(131)
Adult
(128)
Aged
(125)
Antineoplastic Agents
(121)
Pharmacology & Pharmacy
(116)
Neoplasms - Drug Therapy
(100)
Chemotherapy
(92)
Pharmacokinetics
(92)
Antineoplastic Agents - Pharmacokinetics
(86)
Antineoplastic Agents, Phytogenic - Pharmacokinetics
(80)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Contribution of Organic Cation Transporter 2 (OCT2) to Cisplatin-Induced Nephrotoxicity

Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation

Drug Transporters: Advances and Opportunities

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations

Pharmacogenetics of drug transporters

Peripheral neuropathy: A persisting challenge in paclitaxel-based regimes

Pharmacogenetic Pathway Analysis of Docetaxel Elimination

A Snapshot of Challenges and Solutions in Cancer Drug Development and Therapy

Dosing strategies for anticancer drugs: the good, the bad and body-surface area

Pharmacological effects of formulation vehicles: Implications for cancer chemotherapy

Advances in Cancer Therapeutics

Integrating Clinical Pharmacology Concepts in Individualized Therapy With Tyrosine Kinase Inhibitors

Conjunctive Therapy of Cisplatin With the OCT2 Inhibitor Cimetidine: Influence on Antitumor Efficacy and Systemic Clearance

Clinical Pharmacokinetics and Metabolism of Irinotecan (CPT-11)

Role of Body Surface Area in Dosing of Investigational Anticancer Agents in Adults, 1991–2001

Irinotecan-induced Diarrhea: Functional Significance of the Polymorphic ABCC2 Transporter Protein

Dose banding as an alternative to body surface area-based dosing of chemotherapeutic agents

Inhibition of OATP1B1 by tyrosine kinase inhibitors: in vitro-in vivo correlations

Drug Trafficking: Recent Advances in Therapeutics and Disease

Inherited variation in OATP1B1 is associated with treatment outcome in acute myeloid leukemia

Associations Between ABCC2 Polymorphisms and Cisplatin Disposition and Efficacy

Environmental and Genetic Factors Affecting Transport of Imatinib by OATP1A2

Influence of Solute Carriers on the Pharmacokinetics of CYP3A4 Probes

Variants in the SLCO1B3 Gene: Interethnic Distribution and Association with Paclitaxel Pharmacokinetics

Suchergebnisse filtern